Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial

医学 安慰剂 祖细胞 冲程(发动机) 内科学 骨髓 外科 干细胞 病理 遗传学 机械工程 生物 工程类 替代医学
作者
David C. Hess,Lawrence R. Wechsler,Wayne M. Clark,Sean I. Savitz,Gary A. Ford,David Chiu,Dileep R Yavagal,Ken Uchino,David S. Liebeskind,Alexander P. Auchus,Souvik Sen,Cathy Sila,Jeffrey Vest,Robert Mays
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:16 (5): 360-368 被引量:319
标识
DOI:10.1016/s1474-4422(17)30046-7
摘要

Background Multipotent adult progenitor cells are a bone marrow-derived, allogeneic, cell therapy product that modulates the immune system, and represents a promising therapy for acute stroke. We aimed to identify the highest, well-tolerated, and safest single dose of multipotent adult progenitor cells, and if they were efficacious as a treatment for stroke recovery. Methods We did a phase 2, randomised, double-blind, placebo-controlled, dose-escalation trial of intravenous multipotent adult progenitor cells in 33 centres in the UK and the USA. We used a computer-generated randomisation sequence and interactive voice and web response system to assign patients aged 18–83 years with moderately severe acute ischaemic stroke and a National Institutes of Health Stroke Scale (NIHSS) score of 8–20 to treatment with intravenous multipotent adult progenitor cells (400 million or 1200 million cells) or placebo between 24 h and 48 h after symptom onset. Patients were ineligible if there was a change in NIHSS of four or more points during at least a 6 h period between screening and randomisation, had brainstem or lacunar infarct, a substantial comorbid disease, an inability to undergo an MRI scan, or had a history of splenectomy. In group 1, patients were enrolled and randomly assigned in a 3:1 ratio to receive 400 million cells or placebo and assessed for safety through 7 days. In group 2, patients were randomly assigned in a 3:1 ratio to receive 1200 million cells or placebo and assessed for safety through the first 7 days. In group 3, patients were enrolled, randomly assigned, and stratified by baseline NIHSS score to receive 1200 million cells or placebo in a 1:1 ratio within 24–48 h. Patients, investigators, and clinicians were masked to treatment assignment. The primary safety outcome was dose-limiting toxicity effects. The primary efficacy endpoint was global stroke recovery, which combines dichotomised results from the modified Rankin scale, change in NIHSS score from baseline, and Barthel index at day 90. Analysis was by intention to treat (ITT) including all patients in groups 2 and 3 who received the investigational agent or placebo. This study is registered with ClinicalTrials.gov, number NCT01436487. Findings The study was done between Oct 24, 2011, and Dec 7, 2015. After safety assessments in eight patients in group 1, 129 patients were randomly assigned (67 to receive multipotent adult progenitor cells and 62 to receive placebo) in groups 2 and 3 (1200 million cells). The ITT populations consisted of 65 patients who received multipotent adult progenitor cells and 61 patients who received placebo. There were no dose-limiting toxicity events in either group. There were no infusional or allergic reactions and no difference in treatment-emergent adverse events between the groups (64 [99%] of 65 patients in the multipotent adult progenitor cell group vs 59 [97%] of 61 in the placebo group). There was no difference between the multipotent adult progenitor cell group and placebo groups in global stroke recovery at day 90 (odds ratio 1·08 [95% CI 0·55–2·09], p=0·83). Interpretation Administration of multipotent adult progenitor cells was safe and well tolerated in patients with acute ischaemic stroke. Although no significant improvement was observed at 90 days in neurological outcomes with multipotent adult progenitor cells treatment, further clinical trials evaluating the efficacy of the intervention in an earlier time window after stroke (<36 h) are planned. Funding Athersys Inc.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
隐形曼青应助旧辞采纳,获得10
刚刚
何佳完成签到,获得积分10
1秒前
烟花应助coco采纳,获得10
1秒前
小晶完成签到,获得积分10
1秒前
zimablue完成签到,获得积分10
2秒前
慕青应助范先生采纳,获得10
2秒前
zzz完成签到,获得积分10
3秒前
4秒前
海盗船长完成签到,获得积分10
4秒前
等待寄云完成签到 ,获得积分10
4秒前
酷波er应助王冉冉采纳,获得10
5秒前
lcjynwe完成签到,获得积分10
6秒前
新奇完成签到 ,获得积分10
6秒前
Misty_发布了新的文献求助10
6秒前
iNk应助不会取名字采纳,获得20
6秒前
Orange应助Hannes采纳,获得10
6秒前
8秒前
多多少少忖测的情完成签到,获得积分10
8秒前
小马甲应助lx采纳,获得10
8秒前
9秒前
阔达冰兰发布了新的文献求助10
9秒前
GAO完成签到,获得积分10
9秒前
yy发布了新的文献求助10
10秒前
10秒前
10秒前
奋斗冬萱完成签到,获得积分10
10秒前
康园完成签到,获得积分10
11秒前
活泼的面包完成签到,获得积分10
13秒前
123456完成签到,获得积分10
14秒前
重要谷冬完成签到,获得积分10
14秒前
深情丸子发布了新的文献求助10
14秒前
14秒前
杰瑞完成签到,获得积分10
16秒前
16秒前
ding应助科研通管家采纳,获得10
17秒前
Akim应助科研通管家采纳,获得10
17秒前
领导范儿应助科研通管家采纳,获得10
17秒前
fang应助科研通管家采纳,获得10
17秒前
今后应助科研通管家采纳,获得10
17秒前
李小鑫吖发布了新的文献求助10
17秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038524
求助须知:如何正确求助?哪些是违规求助? 3576221
关于积分的说明 11374737
捐赠科研通 3305912
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892688
科研通“疑难数据库(出版商)”最低求助积分说明 815048